ArticlePloS one2013
Tumor necrosis factor B (TNFB) genetic variants and its increased expression are associated with vitiligo susceptibility.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Relationship Between the Levels of 91 Circulating Inflammatory Proteins and Ovarian-Related Diseases: A Bidirectional Mendelian Randomization Study.International journal of women's health · 2025Article
- A Mendelian randomization study on the association between systemic inflammatory regulators and essential and secondary hypertension.Frontiers in cardiovascular medicine · 2024Article
- Mendelian randomization analysis of causal and druggable circulating inflammatory proteins in schizophrenia.Frontiers in psychiatry · 2024Article
- Decreased ZMIZ1 suppresses melanogenesis in vitiligo by regulating mTOR/AKT/GSK-3β-mediated glucose uptake.In vitro cellular & developmental biology. Animal · 2024Article
- Prognostic significance of the genetic variant of lymphotoxin alpha (p.Thr60Asn) in egyptian patients with advanced hepatocellular carcinoma.Molecular biology reports · 2023Article
- Association of rs4711998 of IL-17A, rs2275913 of IL-17A and rs763780 IL-17F gene polymorphisms with non-segmental vitiligo in a Mexican population.Archives of dermatological research · 2023Article
- The Role of Oxidative Stress in Vitiligo: An Update on Its Pathogenesis and Therapeutic Implications.Cells · 2023Review
- The etiological effect and genetic risk of +252 A/G variant of TNF-β gene related to the susceptibility of urinary tract infection in a sample of Iraqi patients with type 2 diabetes: A case control study.Health science reports · 2023Article
- Utilizing the ABC Transporter for Growth Factor Production byBiomedicines · 2021Article
- ZMIZ1 promotes the proliferation and migration of melanocytes in vitiligo.Experimental and therapeutic medicine · 2020Article
- A Concise Review on the Role of Endoplasmic Reticulum Stress in the Development of Autoimmunity in Vitiligo Pathogenesis.Frontiers in immunology · 2020Review
- Multiple selective sweeps of ancient polymorphisms in and around LTα located in the MHC class III region on chromosome 6.BMC evolutionary biology · 2019Article
- TNF-β +252 A>G (rs909253) polymorphism is independently associated with presence of autoantibodies in rheumatoid arthritis patients.Clinical and experimental medicine · 2019Article
- Changes in sICAM-1 and GM-CSF levels in skin tissue fluid and expression of IL-6, IL-17 and TNF-α in blood of patients with vitiligo.Experimental and therapeutic medicine · 2019Article
- Article
- Influence of functional polymorphisms in TNF-α, IL-8, and IL-10 cytokine genes on mRNA expression levels and risk of gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.The British journal of dermatology · 2015Review
- Article
- Association of genetic variants of the vitamin D receptor gene with vitiligo in a tertiary care center in a Saudi population: a case-control study.Annals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic polymorphisms in TNFB are involved in the regulation of its expression and are found to be associated with various autoimmune diseases. The aim of the present study was to determine whether TNFB +252A/G (rs909253) and exon 3 C/A (rs1041981) polymorphisms are associated with vitiligo susceptibility, and expression of TNFB and ICAM1 affects the disease onset and progression. We have earlier reported the role of TNFA in autoimmune pathogenesis of vitiligo, and we now show the involvement of TNFB in vitiligo pathogenesis. The two polymorphisms investigated in the TNFB were in strong linkage disequilibrium and significantly associated with vitiligo. TNFB and ICAM1 transcripts were significantly increased in patients compared to controls. Active vitiligo patients showed significant increase in TNFB transcripts compared to stable vitiligo. The genotype-phenotype analysis revealed that TNFB expression levels were higher in patients with GG and AA genotypes as compared to controls. Patients with the early age of onset and female patients showed higher TNFB and ICAM1 expression. Overall, our findings suggest that the increased TNFB transcript levels in vitiligo patients could result, at least in part, from variations at the genetic level which in turn leads to increased ICAM1 expression. For the first time, we show that TNFB +252A/G and exon 3 C/A polymorphisms are associated with vitiligo susceptibility and influence the TNFB and ICAM1 expression. Moreover, the study also emphasizes influence of TNFB and ICAM1 on the disease progression, onset and gender bias for developing vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.